Hims & Hers Health (HIMS) Announces Access to GLP-1 Injections
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Hims and Hers (HIMS) PT Raised to $24 at Canaccord Genuity
May 22, 2024 5:29 AM EDTCanaccord Genuity analyst Maria Ripps raised the price target on Hims and Hers (NYSE: HIMS) to $24.00 (from $20.00) while maintaining a Buy rating.
The analyst comments "On Monday, 5/20, Hims & Hers announced the addition of GLP-1 treatment to its portfolio of weight loss solutions, with prices... More
Citi Reiterates Buy Rating on Hims and Hers (HIMS)
May 20, 2024 11:49 AM EDTCiti analyst Daniel Grosslight reiterated a Buy rating and $16.00 price target on Hims and Hers (NYSE: HIMS)
The analyst comments "As widely anticipated, HIMS launched its GLP-1 offering this morning, which we think will significantly increase the interest in its weight loss offering.... More
